Business Description
Solid Biosciences Inc
NAICS : 325411
SIC : 2836
ISIN : US83422E1055
Description
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.71 | |||||
| Equity-to-Asset | 0.77 | |||||
| Debt-to-Equity | 0.21 | |||||
| Debt-to-EBITDA | -0.26 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 40.1 | |||||
| 3-Year EPS without NRI Growth Rate | 42.1 | |||||
| 3-Year FCF Growth Rate | 33.8 | |||||
| 3-Year Book Growth Rate | -35.7 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 19.9 | |||||
| 9-Day RSI | 28.92 | |||||
| 14-Day RSI | 37.64 | |||||
| 6-1 Month Momentum % | 483.93 | |||||
| 12-1 Month Momentum % | 159.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.94 | |||||
| Quick Ratio | 8.94 | |||||
| Cash Ratio | 8.52 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -53.3 | |||||
| Shareholder Yield % | -1.86 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -57.84 | |||||
| ROA % | -45.97 | |||||
| ROIC % | -229.08 | |||||
| ROC (Joel Greenblatt) % | -292.78 | |||||
| ROCE % | -54.6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.61 | |||||
| Price-to-Tangible-Book | 1.61 | |||||
| EV-to-EBIT | -2.62 | |||||
| EV-to-EBITDA | -2.68 | |||||
| EV-to-FCF | -2.85 | |||||
| Price-to-Net-Current-Asset-Value | 2.23 | |||||
| Price-to-Net-Cash | 2.39 | |||||
| Earnings Yield (Greenblatt) % | -38.17 | |||||
| FCF Yield % | -25.37 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers